Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$0.41 - $0.7 $19,002 - $32,442
-46,347 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$0.53 - $1.03 $397,247 - $772,009
-749,524 Reduced 94.18%
46,347 $26,000
Q3 2021

Nov 15, 2021

BUY
$1.0 - $1.18 $196,400 - $231,752
196,400 Added 32.76%
795,871 $820,000
Q2 2021

Aug 16, 2021

BUY
$1.01 - $1.58 $444,905 - $695,990
440,500 Added 277.09%
599,471 $719,000
Q1 2021

May 17, 2021

BUY
$1.23 - $5.98 $116,819 - $567,950
94,975 Added 148.41%
158,971 $207,000
Q4 2020

Feb 16, 2021

BUY
$2.09 - $5.18 $23,042 - $57,109
11,025 Added 20.81%
63,996 $235,000
Q3 2020

Nov 16, 2020

SELL
$1.71 - $2.68 $1,622 - $2,543
-949 Reduced 1.76%
52,971 $113,000
Q2 2020

Aug 14, 2020

SELL
$1.23 - $2.12 $568 - $979
-462 Reduced 0.85%
53,920 $97,000
Q1 2020

May 15, 2020

SELL
$1.06 - $2.15 $21,836 - $44,290
-20,600 Reduced 27.47%
54,382 $72,000
Q4 2019

Feb 14, 2020

SELL
$1.45 - $2.79 $22,185 - $42,687
-15,300 Reduced 16.95%
74,982 $136,000
Q3 2019

Nov 14, 2019

SELL
$2.12 - $3.31 $7,844 - $12,247
-3,700 Reduced 3.94%
90,282 $261,000
Q2 2019

Aug 14, 2019

SELL
$2.37 - $3.97 $3,555 - $5,955
-1,500 Reduced 1.57%
93,982 $251,000
Q1 2019

May 15, 2019

BUY
$2.33 - $3.79 $153,488 - $249,666
65,875 Added 222.5%
95,482 $243,000
Q4 2018

Feb 14, 2019

BUY
$2.77 - $9.38 $15,165 - $51,355
5,475 Added 22.69%
29,607 $82,000
Q3 2018

Nov 14, 2018

BUY
$5.53 - $11.36 $133,449 - $274,139
24,132 New
24,132 $215,000

Others Institutions Holding IDRA

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0

About IDERA PHARMACEUTICALS, INC.


  • Ticker IDRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,296,900
  • Market Cap $188M
  • Description
  • Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating s...
More about IDRA
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.